Newborn Screening and Outcomes for Congenital Adrenal Hyperplasia


About this study

The objective of this study is to evaluate the role of molecular testing to improve newborn screening (NBS) for congenital adrenal Hyperplasia (CAH).

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Children with 21 hydroxylase deficiency and/or either/both biological parent(s)

Exclusion Criteria: 

  • Children who do not have 21 hydroxylase deficiency and their biological parents


Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Aida Lteif, M.D.

Closed for enrollment

Contact information:

Julia Byrne


More information


Publications are currently not available